In addition to the teaching duties of Pharmaceutical Chemistry courses to undergraduate and graduate students at Mansoura University and Dongguk University and during several visiting scientific missions to KIST in South Korea since 2016 to date, My lab at Mansoura Univ. main research is focused on design and synthesis of novel bioactive small molecules for the treatment of different diseases such as cancer, Alzheimer’s, and inflammation. My scientific network has been growing and evolving into a multidisciplinary team, which comprises members with expertise in computer software design, pharmaceutics, chemistry, biophysics, biology, microbiology, and computer science from different countries including South Korea, Egypt, Saudi Arabia, US, and Italy.

Currently, I hold two positions:

Visiting Scholar, Dongguk University-Seoul (College of Pharmacy)

Associate Professor, Pharmaceutical Chemistry Department, Faculty of Pharmacy, Mansoura University, Egypt

01/2016 ~ Now

• Discovered 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: a new modulator for amyloid beta-induced mitochondrial dysfunction.
• Discovered 2-(4-chloro-2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones as TSPO ligands blocking/enhancing Aβ-induced mPTP opening.
• Discovered new pyridyl/pyrazinyl thiourea derivatives as neuroprotective agents against amyloid-β-induced toxicity
• Identified Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders
• Hit discovery of 4-amino-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small library
• Identified 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease
• Repositioned the antipsychotic trifluoperazine into new derivatives as anti-glioblastoma agents
• Discovered 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer’s disease
• Discovered first-in-class thiazolidinedione derivatives as irreversible allosteric IKK-β modulators.